Trial Profile

Neuronal Correlates of Altered States of Consciousness

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergide (Primary)
Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Cluster headache; Major depressive disorder; Pain
Focus Pharmacodynamics

Most Recent Events

12 Jan 2026 According to Definium Therapeutics media release, MindMed is now called as Definium Therapeutics.
01 Jun 2022 Results of pooled analysis from NCT01878942, NCT02308969, NCT03019822, and NCT03321136; evaluating Safety pharmacology of acute LSD administration in healthy subjects, published in the Psychopharmacology
26 May 2021 According to a Mindmed media release, pooled results from four phase I studies were published in the Nature Scientific Reports.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com